{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T09:33:44Z","timestamp":1791020024522,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T00:00:00Z","timestamp":1270080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T00:00:00Z","timestamp":1270080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T00:00:00Z","timestamp":1270080000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T00:00:00Z","timestamp":1270080000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T00:00:00Z","timestamp":1270080000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T00:00:00Z","timestamp":1270080000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T00:00:00Z","timestamp":1270080000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2010,4]]},"DOI":"10.1016\/j.canlet.2009.09.006","type":"journal-article","created":{"date-parts":[[2009,10,13]],"date-time":"2009-10-13T05:05:57Z","timestamp":1255410357000},"page":"182-191","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":78,"title":["Celastrol, a novel HSP90 inhibitor, depletes Bcr\u2013Abl and induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation"],"prefix":"10.1016","volume":"290","author":[{"given":"Zhongzheng","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanli","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingrong","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingxuan","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2009.09.006_bib1","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1158\/0008-5472.CAN-07-3293","article-title":"Oncogene addiction","volume":"68","author":"Weinstein","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2009.09.006_bib2","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1101\/gad.1609907","article-title":"Oncogene addiction: setting the stage for molecularly targeted cancer therapy","volume":"21","author":"Sharma","year":"2007","journal-title":"Genes Dev."},{"key":"10.1016\/j.canlet.2009.09.006_bib3","doi-asserted-by":"crossref","first-page":"10959","DOI":"10.1158\/0008-5472.CAN-06-1216","article-title":"A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia","volume":"66","author":"Chen","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2009.09.006_bib4","doi-asserted-by":"crossref","first-page":"5531","DOI":"10.1128\/MCB.15.10.5531","article-title":"Structural and signaling requirements for BCR\u2013ABL-mediated transformation and inhibition of apoptosis","volume":"15","author":"Cortez","year":"1995","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.canlet.2009.09.006_bib5","doi-asserted-by":"crossref","first-page":"18S","DOI":"10.1200\/jco.2006.24.18_suppl.6506","article-title":"Long-term benefits of imatinib (IM) for patients newly diagnosed with chronic myelogenous leukemia in chronic phase (CML-CP): the five-year update from the IRIS study","volume":"24","author":"Druker","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2009.09.006_bib6","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1172\/JCI35660","article-title":"Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells","volume":"119","author":"Bellodi","year":"2009","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.canlet.2009.09.006_bib7","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1182\/blood.V99.5.1860","article-title":"S. de Vos, H. Gschaidmeier, D. Hoelzer, O.G. Ottmann, and H.P. Koeffler, Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR\u2013ABL gene mutation","volume":"99","author":"Hofmann","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2009.09.006_bib8","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1182\/blood.V101.2.690","article-title":"BCR\u2013ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571","volume":"101","author":"Donato","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2009.09.006_bib9","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1182\/blood-2002-02-0518","article-title":"Binding of imatinib by alpha(1)-acid glycoprotein","volume":"100","author":"Gambacorti-Passerini","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2009.09.006_bib10","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/blood-2003-12-4276","article-title":"Active transport of imatinib into and out of cells: implications for drug resistance","volume":"104","author":"Thomas","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2009.09.006_bib11","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR\u2013ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.canlet.2009.09.006_bib12","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1038\/sj.leu.2402741","article-title":"Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy","volume":"16","author":"Hochhaus","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2009.09.006_bib13","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1586\/14737140.8.9.1387","article-title":"Abl tyrosine kinase inhibitors for overriding Bcr\u2013Abl\/T315I: from the second to third generation","volume":"8","author":"Tanaka","year":"2008","journal-title":"Expert. Rev. Anticancer Therap."},{"key":"10.1016\/j.canlet.2009.09.006_bib14","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias","volume":"354","author":"Talpaz","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2009.09.006_bib15","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1073\/pnas.0408283102","article-title":"A non-ATP-competitive inhibitor of BCR\u2013ABL overrides imatinib resistance","volume":"102","author":"Gumireddy","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.canlet.2009.09.006_bib16","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/nrd2324","article-title":"Flying under the radar: the new wave of BCR\u2013ABL inhibitors","volume":"6","author":"Quintas-Cardama","year":"2007","journal-title":"Nat. Rev. Drug. Discov."},{"key":"10.1016\/j.canlet.2009.09.006_bib17","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1038\/leu.2008.74","article-title":"Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism","volume":"22","author":"Zhang","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2009.09.006_bib18","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1182\/blood-2005-07-2966","article-title":"Adaphostin-induced oxidative stress overcomes BCR\/ABL mutation-dependent and -independent imatinib resistance","volume":"107","author":"Chandra","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2009.09.006_bib19","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1182\/blood-2002-05-1361","article-title":"BCR\u2013ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90","volume":"100","author":"Gorre","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2009.09.006_bib20","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1182\/blood-2006-10-054098","article-title":"Inhibition of heat shock protein 90 prolongs survival of mice with BCR\u2013ABL-T315I-induced leukemia and suppresses leukemic stem cells","volume":"110","author":"Peng","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2009.09.006_bib21","first-page":"5126","article-title":"Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr\u2013Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells","volume":"63","author":"Nimmanapalli","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2009.09.006_bib22","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1158\/1078-0432.CCR-08-2141","article-title":"Triptolide inhibits Bcr\u2013Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation","volume":"15","author":"Shi","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2009.09.006_bib23","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/nrc1716","article-title":"HSP90 and the chaperoning of cancer","volume":"5","author":"Whitesell","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2009.09.006_bib24","first-page":"1799","article-title":"Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr\u2013Abl levels and induces apoptosis and differentiation of Bcr\u2013Abl-positive human leukemic blasts","volume":"61","author":"Nimmanapalli","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2009.09.006_bib25","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.ccr.2006.09.005","article-title":"Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators","volume":"10","author":"Hieronymus","year":"2006","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2009.09.006_bib26","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1158\/1535-7163.MCT-07-0484","article-title":"A novel Hsp90 inhibitor to disrupt Hsp90\/Cdc37 complex against pancreatic cancer cells","volume":"7","author":"Zhang","year":"2008","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.canlet.2009.09.006_bib27","first-page":"1039","article-title":"Effect of a novel tyrosine kinase inhibitor HHGV678 on growth inhibition of Bcr\u2013Abl wild type and IM-resistant cell lines in vitro","volume":"16","author":"Qiu","year":"2008","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"10.1016\/j.canlet.2009.09.006_bib28","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1111\/j.1349-7006.2009.01159.x","article-title":"Activity of triptolide against human mast cells harboring the kinase domain mutant KIT","volume":"100","author":"Jin","year":"2009","journal-title":"Cancer Sci."},{"key":"10.1016\/j.canlet.2009.09.006_bib29","doi-asserted-by":"crossref","DOI":"10.1111\/j.1349-7006.2009.01159.x","article-title":"Activity of triptolide against human mast cells harboring the kinase domain mutant KIT","author":"Jin","year":"2009","journal-title":"Cancer Sci."},{"key":"10.1016\/j.canlet.2009.09.006_bib30","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1182\/blood-2006-04-013805","article-title":"EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation","volume":"109","author":"Pan","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2009.09.006_bib31","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1182\/blood-2005-04-1568","article-title":"Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation","volume":"106","author":"Gotlib","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2009.09.006_bib32","doi-asserted-by":"crossref","first-page":"4758","DOI":"10.1158\/0008-5472.CAN-05-4529","article-title":"Celastrol, a triterpene extracted from the Chinese, Thunder of God Vine, is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice","volume":"66","author":"Yang","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2009.09.006_bib33","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.cell.2007.08.021","article-title":"Molecular understanding and modern application of traditional medicines: triumphs and trials","volume":"130","author":"Corson","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2009.09.006_bib34","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.molmed.2007.07.001","article-title":"From traditional Chinese medicine to rational cancer therapy","volume":"13","author":"Efferth","year":"2007","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.canlet.2009.09.006_bib35","first-page":"327","article-title":"A prospective, Controlled, double-blind, cross-over study of tripterygium wilfodii hook F in treatment of rheumatoid arthritis","volume":"102","author":"Tao","year":"1989","journal-title":"Chin. Med. J. Engl."},{"key":"10.1016\/j.canlet.2009.09.006_bib36","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1182\/blood-2006-10-050807","article-title":"Celastrol, a novel triterpene, potentiates TNF-induced apoptosis and suppresses invasion of tumor cells by inhibiting NF-kappaB-regulated gene products and TAK1-mediated NF-kappaB activation","volume":"109","author":"Sethi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2009.09.006_bib37","doi-asserted-by":"crossref","first-page":"6769","DOI":"10.1158\/1078-0432.CCR-07-1536","article-title":"Preclinical studies of celastrol and acetyl isogambogic acid in melanoma","volume":"13","author":"Abbas","year":"2007","journal-title":"Clin. Cancer Res."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383509005734?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383509005734?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T15:29:18Z","timestamp":1759591758000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383509005734"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["S0304383509005734"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2009.09.006","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2010,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Celastrol, a novel HSP90 inhibitor, depletes Bcr\u2013Abl and induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2009.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}